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Abstract
Background: Increased hemostatic activity is common in many cancer types and often causes additional
complications and even death. Circumstantial evidence suggests that tissue factor pathway inhibitor-1 (TFPI) plays a
role in cancer development. We recently reported that downregulation of TFPI inhibited apoptosis in a breast
cancer cell line. In this study, we investigated the effects of TFPI on self-sustained growth and motility of these
cells, and of another invasive breast cancer cell type (MDA-MB-231).
Methods: Stable cell lines with TFPI (both a and b) and only TFPIb downregulated were created using RNA
interference technology. We investigated the ability of the transduced cells to grow, when seeded at low densities,
and to form colonies, along with metastatic characteristics such as adhesion, migration and invasion.
Results: Downregulation of TFPI was associated with increased self-sustained cell growth. An increase in cell
attachment and spreading was observed to collagen type I, together with elevated levels of integrin a2.
Downregulation of TFPI also stimulated migration and invasion of cells, and elevated MMP activity was involved in
the increased invasion observed. Surprisingly, equivalent results were observed when TFPIb was downregulated,
revealing a novel function of this isoform in cancer metastasis.
Conclusions: Our results suggest an anti-metastatic effect of TFPI and may provide a novel therapeutic approach
in cancer.
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Background
An association between cancer and the hemostatic sys-
tem has been recognized for almost two centuries [1-3].
Thrombosis is nevertheless still among the leading
causes of death in cancer patients [3]. The coagulation
cascade is triggered by tissue factor (TF) and results in
the formation of a fibrin network. TF pathway inhibitor-
1 (TFPI) is mainly known for its role in the hemostatic
system where it is responsible for the inactivation of
TF-induced coagulation [4,5]. There is, however, a grow-
ing body of evidence of a new role of TFPI in cancer.
Elevated levels of plasma TFPI in cancer patients have
previously been reported [6,7], and TFPI expression was
demonstrated in several tumors, including breast cancer
tissue and cells [8,9], indicating a possible involvement
of TFPI in cancer biology [9].
Two main isoforms of TFPI are recognized, TFPIa and
TFPIb. TFPIa consists of three Kunitz-type domains and a
basic C-terminus, and is either secreted or attached to the
cell membrane through an unknown glycosylphosphatidy-
linositol (GPI) linked molecule. TFPIb contains only the
first two Kunitz-domains and has a different C-terminus
with a GPI anchor that attaches it to the cell membrane
[10-13]. The functional role of TFPIb is not yet completely
understood [14]. In a recent study, we demonstrated a
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pro-apoptotic effect of both TFPIa and TFPIb in breast
cancer cells in vitro, while corresponding downregulation
of endogenous TFPI resulted in reduced apoptotic activity
[15]. It has previously been reported that treatment of can-
cer cells with TFPIa, either recombinant or through ecto-
pic overexpression, resulted in reduced primary and
metastatic tumor growth and tumor cell adhesion in mur-
ine models [16,17]. The non-hemostatic activity of TFPIa
has in several cases been reported to be dependent on the
C-terminal part of the protein [18-23], and a peptide cor-
responding to the C-terminus of TFPIa has been shown
to inhibit angiogenesis and tumor growth in vivo [24].
Requirements for malignant cancer cells to form
metastases are to escape from the primary tumor, to
passage through the circulatory system, and to estab-
lish secondary tumors at distant sites. Such movement
requires abnormal growth and adhesion characteristics
and penetration of the extracellular matrix (ECM) sur-
rounding the tumor and vessel organs [25]. Integrins
are cell surface receptors involved in adhering cells to
the ECM and mediate cell movement [26]. Binding of
the ligand mediates attachment to the matrix, while
phosphorylation of the receptor relays spreading of
the cells to the matrix [27] through the formation of
filopodia, lamellipodia, and stress fibers [28]. Matrix
metalloproteinases (MMPs) are proteases which are
able to cleave the ECM and basement membrane and
are thus important for metastasis of cancer cells [29].
In the present study, we investigated how downregula-
tion of TFPI would affect the growth and metastatic
abilities of human breast cancer cells in vitro, and the
possible mechanisms involved. To investigate the sig-
nificance of the C-terminal end of TFPIa, downregula-
tion of only TFPIb was conducted. We show here that
lowered expression of both isoforms of TFPI or only
TFPIb induced cell signaling and self-sufficient
growth, and stimulated adhesion, migration, and inva-
sion of the cells. The increase in invasion was con-
nected to elevated activity of the proteases MMP-2
and MMP-9.
Methods
Cell culture and stable cell lines
The intraductal breast carcinoma cells Sum102 were
grown in Human mammary epithelial cell (HuMEC)
ready medium (Invitrogen, Carlsbad, CA, USA) contain-
ing HuMEC supplements (epidermal growth factor,
hydrocortisone, isoprotenerol, transferrin and insulin)
and Bovine Pituitary Extract (Invitrogen). The human
mammary adenocarcinoma cells MDA-MB-231 were
grown in DMEM (Lonza, Viviere, Belgium) with 10%
fetal bovine serum (FBS, Lonza). Cells were cultured at
37°C in an incubator with a humidified atmosphere and
5% CO2.
Stable cell lines with TFPI downregulated were estab-
lished as previously described [15]. In short, double
stranded cDNAs encoding shRNAs targeting both iso-
forms of TFPI were cloned into the retroviral vector
pSiRPG [30] and co-transfected into HEK293T cells
together with viral helper vectors. Sum102 and MDA-
MB-231 wild type cells were infected with the viral par-
ticles and positive clones were selected by the use of
puromycin. The stable cell line pools with TFPI downre-
gulated were named pSiRPG-shRNA4, -6 and -7. For
downregulation of TFPIb, cDNAs encoding shRNAs
against this isoform were cloned into the pSiRPG vector
and transduced into MDA-MB-231 cells (shRNA
sequences available upon request). The resulting stable
cell line pools were named pSiRPG-shRNA7b and -9b.
Cell lines transduced with an empty vector were used as
controls and named pSiRPG. The downregulation of
TFPI was confirmed both at the mRNA and protein
level using quantitative RT-PCR and total TFPI ELISA,
respectively, as previously described [15]. The self-
designed Taqman assays TFPIa (fwd primer: 5’-CAA-
GAATGTCTGAGGGCATGTAAA-3’, rev primer: 5’-
CTGCTTCTTTCTTTTTCTTTTGGTTT-3’, probe: 5’-
AGGGTTTCATCCAAAGAATATCAAAAGGAGGCC-
3’) and TFPIb (fwd primer: 5’-CAAGGTTCCCA
GCCTTTTTGT-3’, rev primer: 5’-CTTGGTAAATAT-
GAGCCGCATTC-3’, probe: 5’-TCCAACCATCATT
TGTTCCTTCTTTTGT-3’) were used for mRNA quan-
tification of the individual isoforms.
Self-sufficient growth
To study the cells ability to grow when seeded at low
densities, transduced Sum102 cells (0.2, 5, and 10·103)
were seeded in 12-wells trays and grown for minimum 8
days without reaching confluence. Cells were washed
once with phosphate buffered saline (PBS), trypsinized
and counted using Nucleocounter (Chemometec, Aller-
oed, Denmark). In colony formation experiments, 6-
wells trays were pre-coated with a 0.6% agar/medium
mixture before 2.5·104 cells/well were seeded individu-
ally in 1.7 mL medium containing 0.35% agar. Cells
were grown for 4-6 weeks until colonies appeared. Cells
were incubated 1 hour with 100 μL of MTT for visuali-
zation before trays were scanned using a computer
attached scanner (HP Scanjet 8200). Colonies were
counted using the image processing and analysis pro-
gram ImageJ version 1.4.3.67 (Rasband W; National
Institute of Health, Bethesda, MD, http://rsbweb.nih.
gov/ij/index.html).
Adhesion and cell spreading
Transduced cells were starved over night in medium
without supplements (Sum102) or with 1% FBS (MDA-
MB-231) and seeded (5/2.5·104; Sum102/MDA-MB-231)
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in 96-wells trays coated with fibronectin (10 μg/mL),
laminin (10 μg/mL), collagen I or IV (10 μg/mL), vitro-
nectin (0.5 μg/mL), or gelatin (2%). Plates were incu-
bated for 30 minutes and washed gently once with
growth medium. Adhered cells were counted indirectly
by incubation in medium containing 10 μL WST-1 for
30 minutes followed by analysis at wavelengths 450 and
745 nm in a colorimetric plate reader (Benchmark
Microplate Reader, BIO-RAD, Hercules, CA).
For cell spreading analyses, transduced cells were
starved over night and seeded (3/1.5·105; Sum102/MDA-
MB-231) on glass cover slips coated with fibronectin (10
μg/mL), laminin (10 μg/mL) or collagen I (10 μg/mL),
and incubated for 1 hour at 37°C. Cells were washed
once in PBS, fixed in 4% formaldehyde in PBS for 15
minutes at room temperature and washed three times in
PBS. 0.1% Triton in 100x PBS was added, and after 4
minutes the cells were washed three times in PBS. Sub-
sequently, the cells were dyed with 1% rhodamine-con-
jugated phalloidin (Invitrogen) for 30 minutes and
washed twice in PBS and once in water before the cover
slips were mounted on object glasses using flueric
mounting medium (Vector Laboratories Inc., Burlin-
game, CA). Labeled actin was visualized using a fluores-
cence Nikon eclipse TE300 inverted microscope with a
Plan Fluor ELWD 40x/0.60 NA objective (Nikon,
Tokyo, Japan) and appropriate filters. Images were cap-
tured using a Nikon DS-5M-L1 Camera system. The cell
spreading was quantified by measuring the area of the
cells using ImageJ.
Scratch-wound assay
Transduced Sum102 cells were seeded in 6-wells trays
and starved over night in medium without supplements.
A wound was made in the confluent cell monolayer
using sterile pipette tips and the cells were washed
gently once with PBS before adding culture medium
containing 5% serum. Images were captured after 0, 7.5,
and 17 hours using a Nikon eclipse TE300 inverted
microscope with a Plan 10x/0.25 NA objective (Nikon)
and an attached Nikon DS-5M-L1 Camera system. The
width of the wound was measured manually at each
time point.
Cell migration and invasion
Migration of transduced Sum102 and MDA-MB-231
cells was assessed by a modified Boyden`s chamber
method using a 24-wells format with transwell Falcon
HTS Fluoro Blok inserts (8-μm pore size; Becton Dick-
inson, Franklin Lakes, NJ, USA). Cells were starved over
night in medium without supplements (Sum102) or with
1% FBS (MBA-MB-231), detached with 5 mM EDTA in
PBS and seeded (10/5·104; Sum102/MDA-MB-231) in
500 μL of starvation medium in the upper chambers of
the transwell. 750 μL culture medium with 10% FBS was
added to the lower chambers as a chemoattractant, and
the cells were allowed to migrate for 24/16 hours
(Sum102/MDA-MB-231) at 37°C. After incubation, the
medium was removed and inserts washed once in
Hank’s Balanced Salt solution (HBSS). Cells were stained
with Calcein AM for 90 minutes and migrated cells
were detected using a bottom-reading fluorescence
plate-reader (Wallac Victor 1420, Perkin Elmer, Wal-
tham, MA) at excitation/emission wavelengths of 485/
535 nm.
Invasion of transduced Sum102 and MDA-MB-231
cells was assessed as described for the migration assay,
except for the usage of matrigel pre-coated inserts (BD
BioCoat Tumor invasion system, Bedford, MA, USA).
Cells were incubated for 48/24 hours (Sum102/MDA-
MB-231) before labeling. For MMP inhibition experi-
ments, doxycycline hyclate (6 μg/mL, Sigma-Aldrich, St.
Louis, MO) was added to the upper chambers directly
after cell seeding.
Protein assay
Transduced cells were seeded to reach 80% confluency
after thee days and harvested as previously described
[15]. TFPI antigens were measured in the medium and
lysate of cells with the commercial Asserachrom® Total
and Free TFPI ELISA kits (Diagnostica Stago, Asnière,
France), which detect both isoforms of TFPI or only
TFPIa, respectively. Urokinase plasminogen activator
(uPA) antigen levels and plasminogen activator inhibitor
1 (PAI-1) activity were measured in the medium of cells
using the commercial ELISA kits Zymutest uPA antigen
(Hyphen BioMed, Neuville-sur-Oise, France) and Trini-
lize PAI-1 Activity (Trinity Biotech, Jamestown, NY),
respectively. Results were corrected against cellular total
protein measured in the cell lysate.
MMP-2 and MMP-9 activity in conditioned medium
collected from the transduced cells were determined by
gelatin zymography. Sum102 (3.25·105) and MDA-MB-
231 (4·105) cells were seeded in 6-wells trays and grown
for three days before medium was collected and cells
lysed in Tris (tris(hydroxymethyl)aminomethane) lysis
buffer [15] for Western blot analysis of a-tubulin. For
MDA-MB-231 cells, growth medium was replaced with
serum-free AIM-V (Invitrogen) medium the day after
seeding. The serum-free media were separated on 7.5%
polyacrylamide gels containing 0.1% gelatin (type A
from porcine skin, Sigma-Aldrich). After electrophoresis,
gels were washed twice for 20 minutes in 2.5% Triton
X-100 and incubated overnight at 37°C in 50 mm Tris
(pH 7.5), 200 mm NaCl, 5 mm CaCl2 and 0.02% Brij 35
(Sigma-Aldrich). Positive controls for MMP-2 (recombi-
nant, R&D Systems, Abingdon, UK) and MMP-9 [31]
were run with each gel. The gels were stained with 0.1%
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Coomassie Brilliant Blue R-250 and clear bands indi-
cated gelatinolytic activity.
PI-PLC treatment
Transduced Sum102 and MDA-MB-231 cells (5·106)
were distributed into Eppendorf tubes and washed twice
with PBS. Cells were resuspended in 0.55 ml PBS or
PBS containing phosphatidylinositol-phospholipase (PI-
PLC, 0.7 U/mL, Sigma-Aldrich) and incubated for 2
hours at 37°C. After incubation the cells were pelleted
and the supernatant collected. Cell pellets were washed
twice in cold PBS and lysed. Cellular total protein was
measured in the cell lysate and total and free TFPI anti-
gens were measured in the supernatant as described
above.
Western blot analysis
Transduced Sum102 and MDA-MB-231 cells were
starved for 5.5 hours in medium without supplements
and FBS, respectively. 1-2·106 cells were distributed into
Eppendorf tubes and stimulated with growth medium
containing 10% FBS for 0-60 minutes. Cells were
washed twice in PBS and lysed in sample buffer contain-
ing 10% DTT, 0.25% Benzonase, 0.2% aprotinin, 0.6%
100 mM PMSF, and 1.0% phosphatase inhibitor cocktail
and stored at -20°C until use. The cell lysates were incu-
bated at 97°C for 5 minutes before separated on SDS-
polyacrylamide gels (Bio-Rad Laboratories, Hercules,
CA). Membranes were incubated with primary antibody
over night at 4°C and 1 hour at room temperature with
the appropriate horseradish peroxidase (HRP) -conju-
gated secondary antibody. HRP signals were developed
using the ECL Plus Western blotting detection system
(GE Healthcare Bio-Sciences, Uppsala, Sweden). The fol-
lowing human antibodies were used; Anti-phospho-Akt
(Ser473, #9271), anti-phospho-IB (Ser32, #2859), anti-
phospho-NF-B (Ser468, #3039), anti-phospho-44/42
MAPK (Thr202/Tyr204, #4377), anti-phospho-SAPK/
JNK (Thr183/Tyr185, #9251), and anti-phospho-Src
family (Tyr416, #2010) from Cell signaling Technology
(Denver, MA), anti-phosphotyrosine HRP conjugate
(clone 4G10, #16-105) from Millipore (Billerica, MA),
anti-phosphotyrosine PY99 (sc-7020) from Santa Cruz
Biotechnology (Santa Cruz, CA), and anti-CD49b (integ-
rin a2, 611016) from BD Biosciences (San Jose, Ca).
Anti-c-Src (sc-8056, Santa Cruz Biotechnology) and
anti-a-tubulin (#T5168, Sigma-Aldrich) were used as
loading controls.
Statistical analysis
Statistical differences between data from cells with TFPI
downregulated and empty vector pSiRPG control cells
were calculated using Graphpad Prism 5.0 (Graphpad,
San Diego, CA, USA). The unpaired student’s t test was
used after verification of the normal distribution of the
data. The Welch’s correction (for unequal variances)
was applied when appropriate. For data not normally
distributed, the non-parametric Mann-Whitney test was
used. The statistical differences in cell migration at 7.5
and 17 hours and in invasion of untreated and doxycy-
cline-treated cells were calculated using two-way
ANOVA with Bonferroni corrected post-tests. A prob-
ability value (p) of < .05 was considered significant.
Results
Stable cell lines with TFPI downregulated
Stable cell lines were established through viral transduc-
tion and the results of the downregulation are presented
in Tables 1 and 2. To measure TFPI antigen levels we
used two ELISA assays detecting both isoforms of TFPI
(total TFPI ELISA) and only TFPIa (free TFPI ELISA).
A 30-79% decrease in total TFPI antigen was measured
in the medium of either cell types and corresponding
reductions in mRNA levels of both isoforms of TFPI
Table 1 Stable downregulation of both isoforms of TFPI in Sum102 and MDA-MB-231 breast cancer cells.
TFPIa/b mRNA
downregulation,
% of control
Total TFPI ag Total TFPI ag,
PI-PLC/
Untreated
Free TFPI ag,
PI-PLC/
Untreated
Sum102 [15] pSiRPG-shRNA4 60/51 13.0
pSiRPG-shRNA6 35/36 28.1 1.3/n.d n.d/n.d
pSiRPG-shRNA7 46/42 19.0 1.1/n.d 0.1/n.d
pSiRPG (control) 0/0 56.7 2.4/n.d 0.1/0.1
MDA-MB-231 pSiRPG-shRNA4 62/58 3.6
pSiRPG-shRNA6 26/36 12.0 0.7/0.2 0.1/0.2
pSiRPG-shRNA7 41/46 8.2 0.4/0.2 0.1/0.1
pSiRPG (control) 0/0 17.2 1.5/0.3 0.2/0.2
Sum102 and MDA-MB-231 breast cancer cells were transduced with vectors containing shRNAs against TFPI or empty vector pSiRPG as a control. Relative TFPIa
and b mRNA levels were quantified using qRT-PCR and secreted protein (ag) with total TFPI ELISA kit. GPI attached TFPI was measured in the supernatant after
PI-PLC treatment using total and free TFPI ELISA kits (n.d = not detected). Ag levels were corrected against cellular total protein and presented as ng TFPI/mg
total protein.
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were observed (Table 1). In MDA-MB-231 cells, down-
regulation of only the b isoform resulted in a 42-46%
decrease in TFPIb mRNA and a 34-43% decrease in
total TFPI antigen in the cell lysate. No decrease in
TFPIa mRNA or antigen levels was measured (Table 2).
An increase in total TFPI antigen was detected in the
cell supernatant after treatment with the GPI-cleaving
enzyme PI-PLC, compared to untreated cells, and 50%
less TFPI was released in the knockdown cells than in
empty vector control cells (Tables 1 and 2). No increase
in TFPIa antigen was detected after PI-PLC treatment
(Tables 1 and 2). The mRNA expression ratio of TFPIb/
TFPIa was 7% in Sum102 wild type cells and 2% in
MDA-MB-231 wild type cells (results not shown).
Cell growth and colony formation
To explore the possible role of TFPI in cancer cell
growth, we investigated whether downregulation of
TFPI would affect the cells ability to stimulate self-sus-
tained growth. Cells were seeded at very low concentra-
tions (200-10000 cells/well) and their growth rate was
evaluated. The Sum102 cells expressing shRNAs against
TFPI grew significantly better when seeded at 10000
cells/well than empty vector control cells, counting 60-
80% more cells at the day of harvest (Figure 1A). Similar
results were observed when 500 cells/well were seeded,
while cells seeded at a density of 200 cells/well died
(data not shown). We next investigated if downregula-
tion of TFPI would affect the cells ability to form colo-
nies in soft-agar. The results showed that Sum102 cells
with TFPI downregulated formed larger and more than
twice as many colonies than the empty vector control
cells (Figure 1B and 1C). No significant increase in
growth rate or colony formation was observed in the
MDA-MB-231 cells with TFPI downregulated (data not
shown).
Effect of downregulation of TFPI on cell motility
The increase in self-sustained growth observed in
Sum102 cells with TFPI downregulated may also indi-
cate enhanced metastatic growth of these cells. Cell
motility was investigated by measuring adhesion, migra-
tion, and invasion of the transduced cells. For cell-
matrix adhesion experiments, cells were seeded in wells
coated with different ECM components that are ligands
to various integrin receptors. A significant increase (27-
59% and 46%) in adhesion to collagen I was observed in
MDA-MB-231 cells with TFPI or TFPIb downregulated,
respectively (Figure 2A and 2B). No significant increase
in adhesion of Sum102 cells with TFPI downregulated
was detected (Figure 2C), and no differences in the
adhesion of either cell types to the ECM components
laminin, fibronectin, vitronectin, collagen IV or gelatin
were observed in the transduced cells (data not shown).
The integrin receptor a2b1 is able to bind to collagen I
[32]. To examine the possible involvement of this recep-
tor in the enhanced adhesion observed, the a2 subunit
levels were analyzed by Western blot. An increase in
integrin a2 protein was seen in the lysate of MDA-MB-
231 cells with TFPI (Figure 2D) or TFPIb (Figure 2E)
downregulated, while no difference in integrin a2 levels
was observed in the transduced Sum102 cells (Figure
2F).
Next we investigated if downregulation of TFPI
affected cell spreading on collagen I coated glass cover
slips. The results showed that both MDA-MB-231 and
Sum102 cells with lowered TFPI expression were more
extended than control cells (Figure 3A and 3B, respec-
tively). An increase in the formation of actin stress fibers
was also apparent in MDA-MB-231 (upper panels) and
Sum102 (lower panels) cells expressing shRNA4 (left),
-6 (middle left) and -7 (middle right) against TFPI com-
pared to empty vector control cells (right) (Figure 3D,
white arrows). Similar results were observed when only
TFPIb was downregulated. As seen in Figures 3C and
3E (white arrows), cells were more extended compared
to the empty vector control cells and actin stress fibers
were clearly visible in cells expressing shRNA7b (left
panel) and -9b (middle panel) against TFPIb compared
to control cells (right panel).
To further investigate the effect of downregulation of
TFPI on cell motility, we analyzed the cells ability to
migrate. In the scratch wound assay, Sum102 cells
expressing shRNA4 (white bars), -6 (light gray bars) and
-7 (dark gray bars) against TFPI migrated faster into the
wound compared to empty vector control cells (black
Table 2 Stable downregulation of TFPIb in MDA-MB-231 breast cancer cells.
TFPIb/a mRNA
downregulation,
% of control
Total/Free TFPI ag Total TFPI ag,
PI-PLC/Untreated
Free TFPI ag,
PI-PLC/Untreated
MDA-MB-231 pSiRPG-shRNA7b 46/2 2.0/1.6 0.7/0.2 0.1/0.1
pSiRPG-shRNA9b 42/1 2.3/1.6 0.8/0.2 0.1/0.1
pSiRPG (control) 0/0 3.5/1.7 1.5/0.3 0.2/0.2
MDA-MB-231 breast cancer cells were transduced with vectors containing shRNAs against TFPIb or empty vector pSiRPG as a control. Relative TFPIa and b mRNA
levels were quantified using qRT-PCR and cell-associated protein (ag) with total and free TFPI ELISA kits. GPI attached TFPI was measured in the supernatant after
PI-PLC treatment using total and free TFPI ELISA kit. Ag levels were corrected against cellular total protein and presented as ng TFPI/mg total protein.
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bars) (Figure 4A and 4B). 24-38% of the cell wounds
were closed after 7.5 hours of serum stimulation when
TFPI was downregulated, compared to 15% in the con-
trol cells. After 17 hours, 55-79% of the wounds were
closed in the knockdown cells, but only 49% in the con-
trols. The effect of downregulation of TFPI on chemo-
taxis was also investigated using modified Boyden
chambers where cells migrate through pores towards an
attractant. Sum102 cells expressing shRNA6 and -7
against TFPI showed a significant 210% and 100%
increase in migration, respectively, compared to control
cells (Figure 4C). Moreover, a significant 50% increase
in migration of MDA-MB-231 cells expressing shRNA6
against TFPI was also observed (Figure 4D). Downregu-
lation of TFPIb resulted in a significant 40% and 60%
increase in MDA-MB-231 cell migration (Figure 4E).
To investigate whether downregulation of TFPI
would affect the cells invasive abilities, we used modi-
fied Boyden chambers coated with matrigel to mimic
the ECM. Compared to the empty vector control cells,
a significant 100% and 120% increase in invasion were
observed in Sum102 cells expressing shRNA6 and -7
against TFPI, respectively (Figure 5A). In MDA-MB-
231 cells expressing shRNA6 and -7 against TFPI, a
Figure 1 Self-sustained growth of Sum102 cells after downregulation of TFPI. (A) Sum102 cells expressing shRNA4 or -7 against TFPI or
pSiRPG empty control were seeded at 10000 cells/well in 12-wells trays and grown for a minimum of 8 days. The results are presented as mean
cell count (n = 9) + SEM of three independent experiments (**p = .0039 and ***p = .0003 against pSiRPG). (B and C) For colony formation
assays, transduced Sum102 cells were seeded individually in soft-agar and grown for 2 to 4 weeks. Colonies were counted using ImageJ and the
results are presented as mean number of colonies (n = 3) + SD of one representative experiment (*p < .046 and ***p = .0006 against pSiRPG).
Scale bar = 1 cm.
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significant 70% and 90% increase in invasion was
detected, respectively, compared to control cells (Fig-
ure 5B). A significant 100% and 140% increase in cell
invasion was seen when only TFPIb was downregulated
(Figure 5C).
The plasminogen activator system, MMP activity, and
intracellular signaling
Plasmin and the plasminogen activator system may
directly or indirectly affect the migration and invasion
of cells [33,34]. To investigate if this system could be
responsible for the increased motility observed in cells
with TFPI downregulated, the plasmin activator, uPA,
and its inhibitor, PAI-1, were analyzed. The results
showed no increase in uPA antigen levels or in PAI-1
activity in the medium of the transduced Sum102 and
MDA-MB-231 cells (data not shown). MMPs are able to
cleave ECM and are therefore important for the invasion
of cancer cells [29]. To investigate the possible involve-
ment of these proteases, gelatin zymography analyses
were performed. The results showed an increase in
MMP-2 activity in Sum102 cells with TFPI downregu-
lated (Figure 6A). In MDA-MB-231 cells, elevated
MMP-9 activity was observed when both isoforms of
TFPI or just TFPIb was downregulated (Figure 6B).
Insignificant MMP-9 and MMP-2 activity was detected
in the Sum102 and MDA-MB-231 cells, respectively. To
confirm that MMPs were involved in the increased inva-
sion observed, the general MMP inhibitor doxycycline
hyclate was added to the upper chamber in the invasion
assays at a non-cytotoxic concentration. The results
showed that the relative invasion was reduced by 24-
41% following doxycycline treatment of Sum102 cells
expressing shRNAs against TFPI. This reduction was
significant in shRNA6 expressing cells (Figure 6C, gray
bars; untreated, dark gray bars; doxycycline treated). In
MDA-MB-231 cells, doxycycline treatment significantly
reduced the relative invasion by 34-35% when shRNA6
and -7 were expressed (Figure 6D). In cells with TFPIb
downregulated, a 16-43% reduction in relative invasion
was observed (Figure 6E).
The molecular mechanisms responsible for the
increase in cell motility observed after downregulation
of TFPI were unclear. To investigate this we analyzed
the phosphorylation status of several signal transduction
molecules known to be involved in these processes. The
results showed increased tyrosine phosphorylation of a
protein just under 80 kDa in both Sum102 (Figure 7A)
and MDA-MB-231 (Figure 7B) cells expressing shRNA6
(lane 1) and -7 (lane 2) against TFPI compared to con-
trol cells (lane 3). Similar results were obtained in
MDA-MB-231 cells expressing shRNA7b (lane 1) and
-9b (lane 2) against TFPIb compared to control cells
(lane 3) (Figure 7C). An increase in tyrosine 416 phos-
phorylation of a Src family member was also seen in
MDA-MB-231 cells with TFPI (Figure 7D, shRNA6;
lane 1, shRNA7; lane 2) and TFPIb (Figure 7E,
shRNA7b; lane 1, shRNA9b; lane 2) downregulated
compared to empty vector control cells (lanes 3). No
Figure 2 Adhesion of cells to collagen I and integrin a2
expression. Transduced cells were seeded in collagen I coated 96-
wells trays and incubated for 30 minutes before attached cells were
analyzed using WST-1. Results are presented as mean relative
adhesion + SEM of three to four independent experiments. (A)
MDA-MB-231 cells expressing shRNAs against TFPI and empty vector
control (n = 24, ***p ≤ .001 against pSiRPG). (B) MDA-MB-231 cells
expressing shRNAs against TFPIb and empty vector control (n = 18,
***p < .0001 against pSiRPG). (C) Sum102 cells expressing shRNAs
against TFPI and empty vector control (n = 18). Integrin a2 protein
levels were measured in the total lysate of MDA-MB-231 cells with
TFPI (D) and TFPIb (E) downregulated, and of (F) Sum102 cells with
TFPI downregulated using Western blot analysis. c-Src was used as
loading control. One representative experiment of two to three is
presented.
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Figure 3 Cell spreading to collagen I. Transduced cells were incubated on collagen I coated glass cover slips, fixed and treated with the F-
actin binding protein phalloidin. Images were retrieved using a fluorescence Nikon eclipse TE300 inverted microscope with a Plan Fluor ELWD
40x/0.60 NA objective (Nikon Tokyo, Japan) attached to a Nikon DS-5M-L1 Camera system. The cell spreading was quantified by measuring the
area of individual cells in a randomly picked field using ImageJ. Results are presented as mean cell area + 95% CI of one representative
experiment of two to three. (A) MDA-MB-231 cells (n ≥ 19, **p = .0017 and ***p < .0001 against pSiRPG) and (B) Sum102 cells (n ≥ 5, *p = .0137
and ***p < .0001 against pSiRPG) with TFPI downregulated. (C) MDA-MB-231 with TFPIb downregulated (n ≥ 19, ***p < .0001 against pSiRPG).
(D) Visualization of the actin stress fibers in MDA-MB-231 (upper panels) and Sum102 (lower panels) cells expressing shRNA4 (left), -6 (middle
left), and -7 (middle right) against TFPI or pSiRPG control vector (right) and in (E) MDA-MB-231 cells expressing shRNA7b (left) and -9b (middle)
against TFPIb or empty control vector (right). Scale bar = 20 μm.
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increase in the phosphorylation status of Akt, IB,
NFB, ERK1/2, and SAPK/JNK was observed in the
transduced cells at the time points tested (data not
shown).
Discussion
TFPI is mainly recognized for its activity in the coagula-
tion cascade. Previous findings have, however, indicated
an additional role of TFPI in cancer biology. We
recently showed that shRNA mediated downregulation
of TFPI inhibited apoptosis, while ectopic overexpres-
sion of TFPI induced apoptosis in breast cancer cells,
supporting this hypothesis [15]. In the present study, we
demonstrate that stable downregulation of both isoforms
of TFPI and TFPIb alone enhanced the metastatic
growth of breast cancer cells by increasing cell spread-
ing, migration and invasion. The phosphorylation status
of signaling molecules was affected and elevated MMP-2
and MMP-9 activity was observed that could explain the
increased cell invasion. These results further supports
an anti-tumor effect of TFPI and indicate a new role of
TFPIb in cancer motility.
The effects of downregulation of TFPI were investigated
in the two basal-like invasive breast carcinoma cell types
Sum102 and MDA-MB-231. These cells are derived from
a primary and a metastatic tumor, respectively, and both
Figure 4 Migration of transduced cells. (A) Scratch wound migration of Sum102 cells expressing pSiRPG-shRNA4 (white bars), -6 (light gray
bars), -7 (dark gray bars) or control vector pSiRPG (black bars). Images were captured using a Nikon eclipse TE300 inverted microscope with a
Plan 10x/0.25 NA objective (Nikon) and an attached Nikon DS-5M-L1 Camera system. Results are presented as the average width of the wound
(n = 4) + SEM of one representative experiment of two (*p <.05 against pSiRPG). (B) Scratch wound widths after 0, 7.5 and 17 hours in cells
expressing shRNA6 against TFPI (left) or pSiRPG control vector (right). Migration of transduced cells was also measured using the modified
Boyden method. Cells were incubated for 24/16 hours (Sum102/MDA-MB-231) at 37°C before stained with Calcein AM for 90 minutes. Results are
presented as mean relative migration + SEM of three to four independent experiments. (C) Sum102 cells (n ≥ 8, *p = .0143 and **p = .0051
against pSiRPG) and (D) MDA-MB-231 cells (n = 9, *p = .0177 against pSiRPG) with TFPI downregulated. (E) MDA-MB-231 cells with TFPIb
downregulated (n = 9, *p = .0103 and **p < .0027 against pSiRPG).
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express endogenous TFPI; the Sum102 cells approximately
four times more than the MDA-MB-231 cells (Table 1).
Stable downregulation of TFPI was conducted using RNA
interference, and shRNAs targeting both isoforms of TFPI
or only TFPIb, were used. In the MDA-MB-231 cells with
TFPIb downregulated, no decrease in TFPIa antigen was
measured verifying that the knockdown was isoform speci-
fic. PI-PLC treatment of the transduced cells resulted in
the release of TFPI from the cell surface. This was only
detectable when total TFPI antigen was measured and
confirmed that TFPIb was attached to the cell surface
through a GPI anchor. Also, less TFPI was released in the
knockdown cells than in the control cells, which showed
that TFPIb was downregulated at the protein level. The
functional effects observed in this study following downre-
gulation of TFPI did not appear to be dose-dependent.
Sum102 cells with TFPI downregulated grew better
when seeded at low densities and formed more colonies
than control cells. This indicated an increased ability to
stimulate self-sufficient growth, both dependent and
independent of cell anchorage. Self-sufficient growth sig-
naling often involves changes in expression or activity of
growth factors, receptors and signaling molecules in the
cells [25]. No increase in cell growth was observed when
empty vector control cells were treated with medium
taken from knockdown cells seeded at low density
(results not shown). This could indicate that the
increase in growth signaling was not due to elevated
secretion of growth factors but rather to enhanced
expression or activity of cell surface receptors and/or
signaling molecules. The induced intracellular signaling
observed in cells with TFPI downregulated may support
this. No effect of downregulation of TFPI was observed
on the self-sustained growth of MDA-MB-231 cells in
this study. The reason for this is unclear although the
two cell types Sum102 and MDA-MB-231 grow at dif-
ferent rates.
The increase in adhesion and stress fiber formation
observed in MDA-MB-231 cells to an ECM component
indicated that downregulation of TFPI enhanced the
integrin-mediated adhesion and -cell spreading of these
cells. Moreover, as the increase in adhesion and cell
spreading was specific to collagen I, and not to the
other ECM components tested, it implied that downre-
gulation of TFPI resulted in enhanced expression and/or
activity of collagen I-binding integrins, such as a2b1
[32]. No difference in adhesion to collagen I was mea-
sured in the transduced Sum102 cells, although the cells
were more extended and an increase in actin stress fiber
formation were observed when TFPI was downregulated.
This indicated an affect on integrin-mediated cell
spreading only. Enhanced protein expression of the a2
integrin subunit was only found in MDA-MB-231 cells
after downregulation of TFPI, which may explain the
increased adhesion observed in these cells. Provencal
and coworkers [35] previously reported that recombi-
nant TFPI (rTFPI) had no effect on adhesion of U-87
glioblastoma cells to gelatin, which is in line with our
results (data not shown). Moreover, in this study rTFPI
was reported to have no effect on the migration of brain
cancer cells, when the membrane was coated with
gelatin.
The molecular mechanisms and processes responsible
for the increase in motility observed in cells with TFPI
downregulated are not known. The elevated MMP-2
and MMP-9 activity measured in these cells indicated
that such proteases are involved in the increased cell
invasion detected. Enhanced MMP activity does not,
however, explain the increase in adhesion, cell spread-
ing, and migration observed following downregulation of
TFPI, and no evidence for the involvement of the plas-
minogen activator system was found. Thus, other pro-
cesses not investigated in this study must have been
Figure 5 Invasion of transduced cells measured using modified
Boyden chambers. Cells were seeded in matrigel pre-coated
chambers and incubated for 48/24 hours (Sum102/MDA-MB-231) at
37°C before stained with Calcein AM. Results are presented as mean
relative invasion + SEM of three independent experiments. (A)
Sum102 cells (n ≥ 8, **p = .0063 and ***p ≤ .0001 against pSiRPG)
and (B) MDA-MB-231 cells (n ≥ 8, ***p < .0001 against pSiRPG) with
TFPI downregulated. (C) MDA-MB-231 cells with TFPIb
downregulated (n ≥ 8, *p = .0227 and **p = .0098 against pSiRPG).
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affected. The increase in phosphorylation of an 80 kDa
protein and a Src kinase observed in cells with TFPI
downregulated may indicate that these signal transduc-
tion pathways were involved. TF has been shown to pro-
mote tumor cell migration, invasion, growth, and
metastasis [36-40], and Hembrough and colleagues [16]
reported that TFPI suppressed metastatic tumor growth
in vivo through inhibition of TF/FVIIa activity. Both cell
types used in the present study express TF [15,36], and
a possible enhanced TF activity could therefore be
responsible for the increased cell motility observed after
downregulation of TFPI. In a chromogenic substrate
FXa activity assay indirectly measuring cell surface TF
activity, we detected an 80-150% increase in TF activity
in Sum102, but not in MDA-MB-231, cells with TFPI
downregulated (data not shown). This may indicate that
elevated TF activity could have been involved in the
increased motility of Sum102 knockdown cells. We
were, however, unable to detect activation of the MAP
kinase cascade in these cell, which is a common down-
stream effect of TF/FVIIa induced intracellular signaling
[41]. It has previously been shown that treatment of
brain cancer cells with rTFPI did not affect the phos-
phorylation status of the MAP kinases ERK1/2 [35],
which is also consistent with our findings.
TFPIa and TFPIb are the main splice variants tran-
scribed from the TFPI gene but the function of the
TFPIb isoform remains unclear [14]. Surprisingly, down-
regulation of only TFPIb in MDA-MB-231 cells resulted
in increased cell motility. We recently reported that
overexpression of TFPIb induced apoptosis in SK-BR-3
breast cancer cells [15], but no effects of TFPIb on
Figure 6 MMP activity and the effect of the general MMP inhibitor doxycycline hyclate. MMP-2 and MMP-9 activity in serum-free media
of transduced Sum102 (A) and MDA-MB-231 (B) cells, respectively, as determined by gelatin zymography. Transduced cells were seeded in 6-
wells trays and grown for three days. Media were replaced with conditioned medium (Sum102) or serum-free AIM-V medium (MDA-MB-231)
after 24 hours. a-tubulin was used as loading control. One representative experiment of three is shown. (A lane was removed to make the
image smaller in B) The relative invasion of transduced cells untreated (gray bars) or treated with doxycycline hyclate (dark gray bars) was
measured using the modified Boyden chamber method. Doxycycline (6 μg/mL) was added to the upper chambers immediately after cell
seeding. Results are presented as mean relative invasion + SEM of two to three independent experiments. (C) Sum102 cells (n ≥ 8, *p < .05) and
(D) MDA-MB-231 cells (n ≥ 6, *p < .05 and **p < .01) with TFPI downregulated. (E) MDA-MB-231 cells with TFPIb downregulated (n ≥ 6).
Stavik et al. BMC Cancer 2011, 11:357
http://www.biomedcentral.com/1471-2407/11/357
Page 11 of 14
cancer cell motility have previously been published. Our
findings therefore support a novel role of TFPIb in can-
cer cell metastasis. Compared to TFPIa, TFPIb lacks the
third Kunitz domain and has a different C-terminal end
containing a GPI anchor. The importance of the C-
terminal part of TFPIa in non-hemostatic activities has
previously been reported both in vivo [24] and in vitro
[18-24], and TFPIa has been shown to be able to inhibit
cell proliferation by binding to the very low density lipo-
protein receptor (VLDLR) through its Kunitz-3 and C-
terminal domains [19]. The effects on cell motility
observed in the present study after downregulation of
TFPIb indicated, however, that additional mechanisms
were involved since TFPIb lacks the Kunitz-3 domain
and has a different C-terminal end than TFPIa. The two
isoforms of TFPI share the Kunitz-1 and Kunitz-2
domains and it therefore seems plausible that TFPI
induced the anti-tumor effects through association with
an unknown receptor, involving the first two Kunitz
domains, resulting in the tyrosine phosphorylation of an
~75 kDa protein. However, the similar functional effects
observed following downregulation of TFPIb alone and
of both TFPIa and TFPIb may also indicate that TFPIb
was responsible for most of the effects seen in our
study. This was further supported by the low TFPIb/
TFPIa ratio observed in these cells. It is evident that
TFPIb is directly attached to the cell membrane through
a GPI anchor (Table 1 and 2, [13]). GPI anchored pro-
teins are known to be concentrated in areas of the
plasma membrane recognized as lipid rafts [42,43], and
the GPI anchor has been reported to be implicated in
signal transduction [44]. The Src protein family may
also associate with these microdomains and these
kinases have been shown to be involved in cell signaling
stimulated by GPI anchored molecules [45]. Further-
more, endothelial GPI-bound TFPI has previously been
localized to caveolae [46], which are invaginated lipid
rafts [47]. This may indicate that the effect of TFPIb on
cancer cell motility observed in this study could have
been mediated through its GPI anchor.
Conclusions
In summary, downregulation of TFPI induced intracellu-
lar tyrosine signaling and increased the self-sustained
growth and metastatic abilities of breast cancer cell lines
in vitro. Increased signal transduction and cell motility
was also observed after downregulation of just TFPIb
suggesting a new role for this isoform in cancer metas-
tasis. These results may contribute to new therapeutic
approaches in cancer.
Figure 7 Phosphorylation status of signaling molecules in the
total lysate of transduced cells after FBS stimulation. Cells were
starved for 5.5 hours before 1-2 × 106 cells were stimulated with
10% FBS for indicated time points. General tyrosine phosphorylation
in Sum102 (A) and MDA-MB-231 (B) cells expressing shRNA6 (lane
1), -7 (lane 2) or empty vector control (lane 3) and (C) in MDA-MB-
231 cells expressing shRNA7b (lane 1), -9b (lane 2) or empty vector
control (lane 3), detected using anti-4G10 antibody. Src family
phosphorylation in MDA-MB-231 cells expressing (D) shRNA6 (lane
1), -7 (lane 2) or empty vector control (lane 3) and (E) shRNA7b
(lane 1), -9b (lane 2) or empty vector control (lane 3), detected
using anti-phospho-Src antibody. c-Src was used as loading control.
One representative experiment of three is shown.
Stavik et al. BMC Cancer 2011, 11:357
http://www.biomedcentral.com/1471-2407/11/357
Page 12 of 14
Acknowledgements and Funding
This work was funded by research grants form the South-Eastern Norway
Regional Health Authority, Hamar, Norway. We would like to thank MSc Ida
Evenrød for helpful assistance with the Western blots and Marie-Christine
Mowinckel for the FXa measurements.
Author details
1Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
2Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3Department
of Haematology, Oslo University Hospital, Oslo, Norway.
Authors’ contributions
MS, NI, MT, LZ, and BS performed experiments; BS designed experiments,
analyzed results and wrote the paper; H-CÅ provided and interpreted
western blot analyses and edited the paper; GS, PMS and NI planned the
project, interpreted results and edited the paper; NI designed the research.
All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 March 2011 Accepted: 17 August 2011
Published: 17 August 2011
References
1. Bouillaud S: De l’Obliteration des veines et de son influence sur la
formation des hydropisies partielles: consideration sur la hydropisies
passive et general. Arch Gen Med 1823, 1:188-204.
2. Trousseau A: Phlegmasia alba dolens. In Clinique medicale de l’Hotel-Dieu
de Paris.. 2 edition. Edited by: Trousseau A. Paris: Balliere J.-B.et fils;
1865:654-712.
3. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW: Cancer and
thrombosis: from molecular mechanisms to clinical presentations. J
Thromb Haemost 2007, 5:246-254.
4. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP: Structure and biology of tissue
factor pathway inhibitor. Thromb Haemost 2001, 86:959-972.
5. Price GC, Thompson SA, Kam PCA: Tissue factor and tissue factor pathway
inhibitor. Anaesthesia 2004, 59:483-492.
6. Lindahl AK, Sandset PM, Abildgaard U, Andersson TR, Harbitz TB: High
Plasma-Levels of Extrinsic Pathway Inhibitor and Low-Levels of Other
Coagulation Inhibitors in Advanced Cancer. Acta Chir Scand 1989,
155:389-393.
7. Iversen N, Lindahl AK, Abildgaard U: Elevated TFPI in malignant disease:
relation to cancer type and hypercoagulation. Br J Haematol 1998,
102:889-895.
8. Kurer MA: Protein and mRNA expression of tissue factor pathway
inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol
Biol Rep 2007, 34:221-224.
9. Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W: Expression of tissue factor
pathway inhibitor (TFPI) in human breast and colon cancer tissue.
Thromb Haemost 2010, 103:198-204.
10. Lwaleed BA, Bass PS: Tissue factor pathway inhibitor: structure, biology
and involvement in disease. J Pathol 2006, 208:327-339.
11. Zhang J, Piro O, Lu L, Broze GJ: Glycosyl phosphatidylinositol anchorage
of tissue factor pathway inhibitor. Circulation 2003, 108:623-627.
12. Maroney SA, Cunningham AC, Ferrel J, Hu R, Haberichter S, Mansbach CM,
Brodsky RA, Dietzen DJ, Mast AE: A GPI-anchored co-receptor for tissue
factor pathway inhibitor controls its intracellular trafficking and cell
surface expression. J Thromb Haemost 2006, 4:1114-1124.
13. Piro O, Broze GJ: Comparison of cell-surface TFPI alpha and beta. J
Thromb Haemost 2005, 3:2677-2683.
14. Crawley JTB, Lane DA: The Haemostatic Role of Tissue Factor Pathway
Inhibitor. Arterioscler Thromb Vasc Biol 2008, 28:233-242.
15. Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N: Overexpression of
both TFPIalpha and TFPIbeta induces apoptosis and expression of genes
involved in the death receptor pathway in breast cancer cells. Mol
Carcinog 2010, 49:951-963.
16. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ,
Pribluda VS: Tissue Factor/Factor VIIa Inhibitors Block Angiogenesis and
Tumor Growth Through a Nonhemostatic Mechanism. Cancer Res 2003,
63:2997-3000.
17. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H,
Francis JL: Tissue factor pathway inhibitor reduces experimental lung
metastasis of B16 melanoma. Thromb Haemost 2002, 87:930-936.
18. Hamuro T, Kamikubo Y, Nakahara Y, Miyamoto S, Funatsu A: Human
recombinant tissue factor pathway inhibitor induces apoptosis in
cultured human endothelial cells. FEBS Lett 1998, 421:197-202.
19. Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK: Tissue
factor pathway inhibitor inhibits endothelial cell proliferation via
association with the very low density lipoprotein receptor. J Biol Chem
2001, 276:12241-12248.
20. Kamikubo Yi, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A:
Human recombinant tissue-factor pathway inhibitor prevents the
proliferation of cultured human neonatal aortic smooth muscle cells.
FEBS Lett 1997, 407:116-120.
21. Liang W, Cheng J, Liu R, Wang Jp, Mu Jg, Wang Qh, Wang Hj, Ma D:
Peptide corresponding to the C terminus of tissue factor pathway
inhibitor inhibits mesangial cell proliferation and activation in vivo.
Peptides 2009, 30:2330-2336.
22. Lin YF, Zhang N, Guo HS, Kong DS, Jiang T, Liang W, Zhao ZH, Tang QQ,
Ma D: Recombinant tissue factor pathway inhibitor induces apoptosis in
cultured rat mesangial cells via its Kunitz-3 domain and C-terminal
through inhibiting PI3-kinase/Akt pathway. Apoptosis 2007, 12:2163-2173.
23. Shirotani-Ikejima H, Kokame K, Hamuro T, Bu G, Kato H, Miyata T: Tissue
factor pathway inhibitor induces expression of JUNB and GADD45B
mRNAs. Biochem Biophys Res Commun 2002, 299:847-852.
24. Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L,
Plum SM, Williams MS, Strickland DK, Pribluda VS: Identification and
characterization of a very low density lipoprotein receptor-binding
peptide from tissue factor pathway inhibitor that has antitumor and
antiangiogenic activity. Blood 2004, 103:3374-3380.
25. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
26. Felding-Habermann B: Integrin adhesion receptors in tumor metastasis.
Clin Exp Metastasis 2003, 20:203-213.
27. Panetti TS: Tyrosine phosphorylation of paxillin, FAK, and p130CAS:
Effects on cell spreading and migration. Front Biosci 2002, 7:D143-D150.
28. Defilippi P, Olivo C, Venturino M, Dolce L, Silengo L, Tarone G: Actin
cytoskeleton organization in response to integrin-mediated adhesion.
Microsc Res Tech 1999, 47:67-78.
29. Chambers AF, Matrisian LM: Changing views of the role of matrix
metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89:1260-1270.
30. Storvold GL, Gjernes E, Askautrud HA, Borresen-Dale AL, Perou CM,
Frengen E: A retroviral vector for siRNA expression in mammalian cells.
Mol Biotechnol 2007, 35:275-282.
31. Winberg JO, Berg E, Kolset SO, Uhlin-Hansen L: Calcium-induced activation
and truncation of promatrix metalloproteinase-9 linked to the core
protein of chondroitin sulfate proteoglycans. Eur J Biochem 2003,
270:3996-4007.
32. McCall-Culbreath KD, Zutter MM: Collagen receptor integrins: Rising to
the challenge. Curr Drug Targets 2008, 9:139-149.
33. Stefansson S, Lawrence DA: Old Dogs and New Tricks, Proteases,
Inhibitors, and Cell Migration. Sci STKE 2003, 2003:e24.
34. Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system
in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57:25-40.
35. Provencal M, Michaud M, Beaulieu E, Ratel D, Rivard GE, Gingras D,
Beliveau R: Tissue factor pathway inhibitor (TFPI) interferes with
endothelial cell migration by inhibition of both the Erk pathway and
focal adhesion proteins. Thromb Haemost 2008, 99:576-585.
36. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK,
Pendurthi UR, Rao LV: Tissue factor-factor VIIa-specific up-regulation of IL-
8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in
increased cell migration. Blood 2004, 103:3029-3037.
37. Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RC:
Role of tissue factor expression on tumour cell invasion and growth of
experimental pancreatic adenocarcinoma. Br J Surg 1999, 86:890-894.
38. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL,
Mackman N, Rak JW: Oncogenic events regulate tissue factor expression
in colorectal cancer cells: implications for tumor progression and
angiogenesis. Blood 2005, 105:1734-1741.
39. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-
Habermann B, Takada Y, Mueller BM, Ruf W: Inhibition of tissue factor
signaling suppresses tumor growth. Blood 2008, 111:190-199.
Stavik et al. BMC Cancer 2011, 11:357
http://www.biomedcentral.com/1471-2407/11/357
Page 13 of 14
40. Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT,
Anderson GM: CNTO 859, a humanized anti-tissue factor monoclonal
antibody, is a potent inhibitor of breast cancer metastasis and tumor
growth in xenograft models. Int J Cancer 2007, 120:1261-1267.
41. Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ: Tissue factor and
cancer metastasis: the role of intracellular and extracellular signaling
pathways. Mol Med 2004, 10:6-11.
42. Trotter J, Klein C, Kramer EM: GPI-anchored proteins and
glycosphingolipid-rich rafts: Platforms for adhesion and signaling.
Neuroscientist 2000, 6:271-284.
43. Horejsi V, Drbal K, Cebecauer M, Cerny J, Brdicka T, Angelisova P,
Stockinger H: GPI-microdomains: a role in signalling via
immunoreceptors. Immunol Today 1999, 20:356-361.
44. Paulick MG, Bertozzi CR: The glycosylphosphatidylinositol anchor: a
complex membrane-anchoring structure for proteins. Biochemistry 2008,
47:6991-7000.
45. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H: GPI-Anchored
Cell-Surface Molecules Complexed to Protein Tyrosine Kinases. Science
1991, 254:1016-1019.
46. Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV,
Lupu F: Tissue factor pathway inhibitor in endothelial cells colocalizes
with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the
anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol
1997, 17:2964-2974.
47. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell
Biol 2000, 1:31-39.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/357/prepub
doi:10.1186/1471-2407-11-357
Cite this article as: Stavik et al.: Downregulation of TFPI in breast cancer
cells induces tyrosine phosphorylation signaling and increases
metastatic growth by stimulating cell motility. BMC Cancer 2011 11:357.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Stavik et al. BMC Cancer 2011, 11:357
http://www.biomedcentral.com/1471-2407/11/357
Page 14 of 14
